MX2021010255A - Oligonucleotidos que interferen con proteina de retraso mental de x fragil y metodos para usar los mismos. - Google Patents

Oligonucleotidos que interferen con proteina de retraso mental de x fragil y metodos para usar los mismos.

Info

Publication number
MX2021010255A
MX2021010255A MX2021010255A MX2021010255A MX2021010255A MX 2021010255 A MX2021010255 A MX 2021010255A MX 2021010255 A MX2021010255 A MX 2021010255A MX 2021010255 A MX2021010255 A MX 2021010255A MX 2021010255 A MX2021010255 A MX 2021010255A
Authority
MX
Mexico
Prior art keywords
fmrp
methods
same
fragile
mental retardation
Prior art date
Application number
MX2021010255A
Other languages
English (en)
Inventor
Francesca Viti
Salvatore Bellinvia
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Publication of MX2021010255A publication Critical patent/MX2021010255A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En el presente documento se describen secuencias de oligonucleótidos en antisentido contra la proteína de retraso mental de X frágil (FMRP) y métodos para usar las mismas para tratar enfermedades intestinales tales como cáncer colorrectal y enfermedad inflamatoria intestinal (por ejemplo, enfermedad de Crohn y colitis ulcerosa), asociadas con una actividad o expresión elevada de FMRP. También se describen composiciones farmacéuticas que contienen un oligonucleótido en antisentido de FMRP útiles para tratar una enfermedad intestinal y la fabricación de medicamentos que contienen el oligonucleótido en antisentido de FMRP dado a conocer, para usarse en el tratamiento de una enfermedad intestinal.
MX2021010255A 2019-02-26 2020-02-26 Oligonucleotidos que interferen con proteina de retraso mental de x fragil y metodos para usar los mismos. MX2021010255A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962810697P 2019-02-26 2019-02-26
PCT/EP2020/055071 WO2020174023A1 (en) 2019-02-26 2020-02-26 Fragile x mental retardation protein interfering oligonucleotides and methods of using same

Publications (1)

Publication Number Publication Date
MX2021010255A true MX2021010255A (es) 2021-12-15

Family

ID=69723929

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010255A MX2021010255A (es) 2019-02-26 2020-02-26 Oligonucleotidos que interferen con proteina de retraso mental de x fragil y metodos para usar los mismos.

Country Status (12)

Country Link
US (1) US20220145303A1 (es)
EP (1) EP3931324A1 (es)
JP (1) JP2022521502A (es)
KR (1) KR20210132678A (es)
CN (1) CN113748207A (es)
AU (1) AU2020228134A1 (es)
BR (1) BR112021016907A2 (es)
CA (1) CA3130854A1 (es)
EA (1) EA202192330A1 (es)
MX (1) MX2021010255A (es)
SG (1) SG11202109112WA (es)
WO (1) WO2020174023A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023122800A1 (en) * 2021-12-23 2023-06-29 University Of Massachusetts Therapeutic treatment for fragile x-associated disorder

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009315898B2 (en) 2008-11-13 2015-07-23 Nogra Pharma Limited Antisense compositions and methods of making and using same
EP2411532B1 (en) * 2009-03-24 2017-04-05 Asuragen, Inc. Pcr methods for characterizing the 5' untranslated region of the fmr1 and fmr2 genes
WO2011056930A2 (en) * 2009-11-06 2011-05-12 Emory University Fragile x mental retardation protein (fmrp), compositions, and methods related thereto
US20130149297A1 (en) * 2010-07-02 2013-06-13 Vib Vzw Role of fragile x mental retardation gene and protein in cancer metastasis
CN103981253A (zh) * 2014-03-27 2014-08-13 江苏佰龄全基因生物医学技术有限公司 一种用于检测脆性x染色体综合征的cgg重复数及agg插入信息的pcr试剂盒
JP2018528968A (ja) * 2015-09-17 2018-10-04 ユニバーシティ オブ マサチューセッツ Ｆｍｒ１発現を調節するための組成物および方法
EP3368089A4 (en) * 2015-10-26 2019-05-29 Translate Bio Ma, Inc. NANOPARTICLE FORMULATIONS FOR ADMINISTRATION OF NUCLEIC ACID COMPLEXES

Also Published As

Publication number Publication date
CN113748207A (zh) 2021-12-03
CA3130854A1 (en) 2020-09-03
AU2020228134A1 (en) 2021-10-14
BR112021016907A2 (pt) 2021-11-03
EP3931324A1 (en) 2022-01-05
EA202192330A1 (ru) 2021-12-13
JP2022521502A (ja) 2022-04-08
KR20210132678A (ko) 2021-11-04
SG11202109112WA (en) 2021-09-29
WO2020174023A1 (en) 2020-09-03
US20220145303A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
SG10201903290YA (en) Modified double-stranded rna agents
MX2023010958A (es) Agentes de arn modificados con efecto reducido fuera de la diana.
CY1119140T1 (el) Συνθεσεις αντικωδικευσης και μεθοδοι κατασκευης και χρησης τους
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
MY142067A (en) Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease
MX2022008744A (es) Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer.
HK1157337A1 (es)
TW200606162A (en) Pyrazolopyridine derivatives
IL186104A (en) Phosphoramidate History of Nucleoside Compounds
WO2015148415A3 (en) Use of the fl118 core chemical structure platform to generate fl118 derivatives for treatment of human disease
MY198880A (en) Phosphoramidate nucleoside derivatives as anticancer agents
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
TW200700093A (en) Pharmaceutical composition for the treatment of cancer
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
TR201819940T4 (tr) Enflamatuar bağırsak hastalığının tedavisi için yöntemler ve bileşimler.
CA3156667A1 (en) OLIGONUCLEOTIDES INCLUDING NUCLEOSIDE ANALOGS
PH12019502660A1 (en) RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
MX2021010255A (es) Oligonucleotidos que interferen con proteina de retraso mental de x fragil y metodos para usar los mismos.
TW200738611A (en) 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
MX2018006445A (es) Oligonucleotidos antisentido de interleucina-34 (il-34) y metodos de uso de los mismos.
MX2022005900A (es) Agentes antisentido de il-34 y metodos de uso de los mismos.
MY148611A (en) Imino-imidazo-pyridine derivatives having antithrombotic activity
WO2020106051A3 (ko) 스트렙토니그린 및 항암제를 모두 포함하는 암 예방 또는 치료에 사용하기 위한 약학적 조성물
Carlson Metastatic Colorectal Cancer: TAS-102, Regorafenib Trials ‘Unequivocally Positive’